eproMene Bio, Inc is a private biotech company located Irvine, California. We are developing novel immune-oncology therapies, such as BAFF-R CAR-T therapy, based on novel antibodies. The BAFF-R CAR-T therapy program, which was discovered and developed at Dr. Larry Kwak’s lab at MD Anderson Cancer Center, Houston, Texas and City of Hope National Medical Center, Duarte, California, was licensed in from City of Hope Natiional Medical Center in April 2017. Further development is on going at City of Hope for its IND enabling study. The company will continue to license and explore additional novel immuno-oncology programs through its network of research partners.
Bryan Hong Woo Kim, Ph.D. CEO
Bryan Hong Woo Kim, Ph.D., is one of the founders of PeproMene Bio and has served as its Chief Executive Officer since March of 2017.
From 2015 to 2017, Dr. Kim was one of the founders of ImmunoMet Therapeutics, Houston Texas where he served as VP of Chemistry as well as Chief Technical Officer. During his tenure he managed the chemistry program of cancer metabolism modulator as well as immune metabolism modulator leading from the discovery program to the clinical development stage.
From 2013 to 2015, Dr. Kim worked as Director of New Drug Discovery at HanAll Biopharma where his responsibilities included taking the lead in medicinal chemistry for development of drugs targeting cancer metabolism and managing the new drug discovery institute.
As a medicinal chemist, Dr. Kim has 22 years of working experience in antiviral, oncology and immuno therapy drugs and has shown successful leadership in projects ranging from drug discovery to clinical trials in several startup biotech companies including Ardea Biosciences, Ribapharm, and Genosco as well as well-established companies such as Valeant and LG Chemical.
Dr. Kim obtained his Ph.D. in organic chemistry from the University of Nebraska, Lincoln where he worked on the synthesis and biological evaluation of novel heavily hexose and nucleoside analogues.